- Home
- MFH vs ERAS Comparison
MFH vs ERAS Comparison
Compare MFH & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFH
- ERAS
- Stock Information
- Founded
- MFH 2011
- ERAS 2018
- Country
- MFH United States
- ERAS United States
- Employees
- MFH N/A
- ERAS N/A
- Industry
- MFH Finance: Consumer Services
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- MFH Finance
- ERAS Health Care
- Exchange
- MFH Nasdaq
- ERAS Nasdaq
- Market Cap
- MFH 382.7M
- ERAS 432.6M
- IPO Year
- MFH N/A
- ERAS 2021
- Fundamental
- Price
- MFH $5.85
- ERAS $1.16
- Analyst Decision
- MFH
- ERAS Strong Buy
- Analyst Count
- MFH 0
- ERAS 6
- Target Price
- MFH N/A
- ERAS $4.83
- AVG Volume (30 Days)
- MFH 64.6K
- ERAS 2.3M
- Earning Date
- MFH 04-25-2025
- ERAS 05-07-2025
- Dividend Yield
- MFH N/A
- ERAS N/A
- EPS Growth
- MFH N/A
- ERAS N/A
- EPS
- MFH N/A
- ERAS N/A
- Revenue
- MFH $716,863.00
- ERAS N/A
- Revenue This Year
- MFH N/A
- ERAS N/A
- Revenue Next Year
- MFH N/A
- ERAS N/A
- P/E Ratio
- MFH N/A
- ERAS N/A
- Revenue Growth
- MFH 119.50
- ERAS N/A
- 52 Week Low
- MFH $1.03
- ERAS $1.01
- 52 Week High
- MFH $8.86
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- MFH 54.51
- ERAS 41.47
- Support Level
- MFH $5.10
- ERAS $1.01
- Resistance Level
- MFH $5.78
- ERAS $1.29
- Average True Range (ATR)
- MFH 0.64
- ERAS 0.17
- MACD
- MFH 0.08
- ERAS 0.00
- Stochastic Oscillator
- MFH 81.48
- ERAS 31.25
About MFH Mercurity Fintech Holding Inc.
Mercurity Fintech Holding Inc is a New York-based digital fintech leader providing access to the rapidly growing AI-powered infrastructure, blockchain, and digital assets sectors. Its three core business lines include: 1. Blockchain and digital asset solutions. 2. AI and HPC infrastructure, specializing in developing liquid cooling solutions for AI data centers. 3. Comprehensive financial services.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.